Human Target Attainment Probabilities for Delafloxacin against Escherichia coli and Pseudomonas aeruginosa

por Hoover, Randall, Marra, Andrea, Duffy, Erin, Cammarata, Sue K
Publicado 2017

2377. Outcomes in Patients With History of Cardiac or Vascular Disease (CV) During Treatment of Acute Bacterial Skin And Skin Structure Infection (ABSSSI) With Delafloxacin (DLX) v...

por Oguchi, Godson, Beasley, Richard, Lawrence, Laura, Tseng, Carol, Cammarata, Sue K
Publicado 2018

Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae isolates from a Phase III community-acquired bacterial pneumonia (CABP) trial

por McCurdy, S P, Sheets, A J, Cammarata, S K, Vidal, J E
Publicado 2021

2378. Resolution of Signs and Symptoms (S&S) of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) With Delafloxacin (DLX) IV/Oral Therapy

por Pullman, John, O’Riordan, William, Lawrence, Laura, Quintas, Megan, Tseng, Carol, Cammarata, Sue K
Publicado 2018

Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function

por Hoover, Randall K., Alcorn, Harry, Lawrence, Laura, Paulson, Susan K., Quintas, Megan, Cammarata, Sue K.
Publicado 2017

A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxaci...

por Kingsley, Jeff, Mehra, Purvi, Lawrence, Laura E., Henry, Eugenia, Duffy, Erin, Cammarata, Sue K., Pullman, John
Publicado 2016

Clinical Pharmacokinetics of Sulfobutylether‐β‐Cyclodextrin in Patients With Varying Degrees of Renal Impairment

por Hoover, Randall K., Alcorn, Harry, Lawrence, Laura, Paulson, Susan K., Quintas, Megan, Luke, David R., Cammarata, Sue K.
Publicado 2018

Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment

por Hoover, Randall, Marbury, Thomas C., Preston, Richard A., Quintas, Megan, Lawrence, Laura E., Paulson, Susan K., Luke, David R., Cammarata, Sue K.
Publicado 2016

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints

por Bhavnani, S. M., Trang, M., Griffith, D. C., Lomovskaya, O., Hammel, J. P., Loutit, J. S., Cammarata, S. K., Dudley, M. N., Ambrose, P. G., Rubino, C. M.
Publicado 2022

Attenuation of oxidant-induced lung injury by 21-aminosteroids (lazaroids): correlation with the mRNA expression for E-selectin, P-selectin, ICAM-1, and VCAM-1.

por Griffin, R L, Krzesicki, R F, Fidler, S F, Rosenbloom, C L, Auchampach, J A, Manning, A M, Haas, J V, Cammarata, S K, Chin, J E, Richards, I M
Publicado 1994

1387. Phase I Study to Evaluate the Safety and Pharmacokinetics (PK) of Single and Multiple Ascending Doses (SAD/MAD) of Intravenous (IV) Minocycline in Healthy Adult Subjects

por Cornely, Oliver A, Arenz, Dorothee, Barraud, Olivier, Bayliss, Mark, Dimitriou, Vassiliki, Hamacher, Stefanie, Lovering, Andrew M, MacGowan, Alasdair, Cammarata, Sue K, Fusaro, Karen, Griffith, David C, Morgan, Elizabeth, Loutit, Jeffery S
Publicado 2018